# REZILIENT4 (NCT07128199)

> A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07128199
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Taiho Oncology, Inc.
- Conditions: Lung Cancer; Adjuvant; Post-surgical; EGFR; Exon 20; Early Stage Lung Cancer; Uncommon EGFR Mutations; NSCLC, Early Stage
- Interventions: TAS6417; Zipalertinib Matching-placebo
- Enrollment: 360
- Primary outcome: Disease-free Survival (DFS) as Assessed by the Investigator

## Indexed commentary on REZILIENT4 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rezilient4-nct07128199
